Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2006-006536-22-Outside-EU/EEA
EUCTR2006-006536-22-Outside-EU/EEAActive, not recruitingNot Applicable

OPEN-LABEL, SINGLE-ARM, MULTICENTER,PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OFADJUNCTIVE ADMINISTRATION OF BRIVARACETAM INSUBJECTS FROM =1 MONTH TO <16 YEARS OLD WITHEPILEPSY

CB Pharma SA0 sites100 target enrollmentStarted: August 7, 2012Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
100
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the parent(s) or legal representative(s). In addition, a Consent form or a specific Assent form, where required, will be signed and dated by minors.
  • •2. Subject/parent(s)/legal representative(s) is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule or medication intake according to the judgment of the Investigator.
  • •3. Localization-related, generalized or undetermined whether focal or generalized epileptic syndrome according to the ILAE classification.
  • •4. Presence of an EEG compatible with the clinical diagnosis of epilepsy.
  • •5. Subject having at least 1 seizure (any type) during the 3 weeks before V1.
  • •6. Subject taking at least 1 but no more than 3 concomitant AEDs. All AEDs need to be at a stable dose for at least 7 days prior to V1 and no additions or deletions of AEDs will be permitted. The dose of any concomitant AED will have to remain stable from V1 through the collection of PK samples. Vagal nerve stimulator stable for at least 2 weeks before V1, is allowed and will be counted as a concomitant AED. Benzodiazepine taken more than once a week (for any indication) will be considered as a concomitant AED.
  • •7. The subject is male or female and is between =1 month and <16 years of age at V1.
  • •8. Body weight at V1 is at least 3kg for infants.
  • •9. Female subjects without childbearing potential (premenarcheal or surgically sterile) are eligible.
  • •10. Female subjects with childbearing potential who are not sexually active are eligible. Subjects need to notify the Investigator if there is an anticipated change in their status.
  • •11. Adolescent female subjects with childbearing potential who are sexually active are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least ethinylestradiol 30µg per intake (or ethinylestradiol 50µg per intake if associated with any strong inducer [eg, carbamazepine, phenobarbital, primidone, phenytoin, oxcarbazepine, St. John’s Wort, rifampicin]),
  • •monogamous relationship with vasectomized partner, or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status.
  • •12. Females with childbearing potential must have a negative pregnancy test at V1.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 100
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Pregnant or nursing females.
  • •2. Concomitant use of LEV at V1. In addition, the use of LEV is prohibited for at least 4 weeks prior to V1.
  • •3. Epilepsy secondary to a progressive cerebral disease or tumor, or any other progressively neurodegenerative disease. Stable arteriovenous malformations, meningiomas or other
  • •benign tumors may be acceptable according to Investigator’s opinion.
  • •4. History of status epilepticus in the last month prior to V1 or during study Baseline.
  • •5. History or presence of pseudoseizures.
  • •6. Subject suffering only from febrile seizures.
  • •7. Subject on felbamate with less than 18 months continuous exposure. Subject who has taken felbamate for a combined duration of treatment and wash out of <18 months before V1.
  • •8. Subjects treated with vigabatrin who have visual field defects.
  • •9. Subject has an allergy to pyrrolidone derivatives, investigational product excipients or a history of multiple drug allergies.
  • •10. Subject has any clinically significant acute or chronic illness (as determined during the physical examination or from other information available to the Investigator: eg, bone marrow depression, chronic hepatic disease, severe renal impairment, psychiatric disorder).
  • •11. Subject has an underlying disease or is receiving a treatment that may interfere with the absorption, distribution, metabolism, and elimination of the study drug.
  • •12. Subject has any medical condition that might interfere with his/her study participation, ie, serious infection, scheduled elective surgery, etc.
  • •13. Subject has a history of suicide attempt or current suicidal ideation and/or behavior.
  • •14. Terminal illness.
  • •15. Subject has any clinically significant deviations from reference range values for laboratory parameters as determined by the Investigator.
  • •16. Clinically relevant ECG abnormality according to Investigator.
  • •17. Subject had major surgery within 6 months prior to V1.
  • •18. Subject received any investigational drug or device within the 30 days prior to V1. The use of AEDs marketed for adults but not approved for pediatric use is not considered to be investigational” for the purposes of this study.
  • •19. Investigators and co-Investigators’ children may not be included as subjects in the study.
  • •20. Subject has impaired hepatic function

Investigators

Sponsor
CB Pharma SA

Similar Trials

Active, not recruiting
Phase 1
STUDY OF ADJUNCTIVE ADMINISTRATION OF BRIVARACETAM INSUBJECTS FROM =1 MONTH TO <16 YEARS OLD WITH EPILEPSYocalization-related, generalized or undetermined whether focal or generalized epileptic syndrome, according to ILAE classificationMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2006-006536-22-BECB Pharma SA100
Active, not recruiting
Not Applicable
STUDY OF ADJUNCTIVE ADMINISTRATION OF BRIVARACETAM INSUBJECTS FROM =1 MONTH TO <16 YEARS OLD WITH EPILEPSYocalization-related, generalized or undetermined whether focal or generalized epileptic syndrome, according to ILAE classificationMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2006-006536-22-PLCB Pharma SA100
Active, not recruiting
Not Applicable
STUDY OF ADJUNCTIVE ADMINISTRATION OF BRIVARACETAM INSUBJECTS FROM =1 MONTH TO <16 YEARS OLD WITH EPILEPSYocalization-related, generalized or undetermined whether focal or generalized epileptic syndrome, according to ILAE classificationMedDRA version: 14.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2006-006536-22-CZCB Pharma SA100
Completed
Phase 2
To determine the safety and efficacy of tablets for patients with inflammation in mouth and lips.
CTRI/2020/08/026991RAJALAKSHMI HOSPITA
Completed
Phase 2
To determine the safety and efficacy of liquid applicator for patients with inflammation in mouth and lips.
CTRI/2020/08/026990RAJALAKSHMI HOSPITA
STUDY OF ADJUNCTIVE ADMINISTRATION OF... | Clinical Trial